MiMedx re­ceives FDA warn­ing let­ter over Ax­iofill man­u­fac­tur­ing con­cerns

The FDA has high­light­ed de­vi­a­tions from cur­rent good man­u­fac­tur­ing prac­tice for MiMedx’s Ax­iofill, a pla­cen­ta-based prod­uct which is un­der re­view re­gard­ing its le­gal clas­si­fi­ca­tion.

Af­ter a man­u­fac­tur­ing in­spec­tion, MiMedx re­ceived a warn­ing let­ter on Dec. 21 that was post­ed on Tues­day, in which the FDA said the com­pa­ny failed to put in place writ­ten pro­ce­dures for pro­duc­tion and process con­trol and lacked sound lab con­trols to en­sure prod­uct iden­ti­ty, strength, qual­i­ty and pu­ri­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER